Pathos has raised a total of $345 million across multiple funding rounds, including a $283 million Series D in April 2025 led by New Enterprise Associates and Revolution. Founded in 2022 and headquartered in Chicago, Pathos achieved unicorn status in just 3 years and 4 months, with a valuation of $1.6 billion. The company leverages AI and patient-derived genomic data to accelerate biomarker-driven drug discovery, optimize clinical-stage therapeutics, and improve patient outcomes, positioning itself as a leading innovator in life sciences and oncology technology.